AGP Picks
View all

Clinical biomarkers market seen reaching $59.44 billion by 2030

2 hours ago
Clinical biomarkers market seen reaching $59.44 billion by 2030
By AI, Created 14:15 UTC, Nov 18, 2026, AGP -

The Business Research Company projects the global clinical biomarkers market will grow from $33.75 billion in 2025 to $59.44 billion by 2030, driven by rising demand for personalized therapies, biomarker-guided drug development and broader use of sequencing and AI tools. North America held the largest regional share in 2025, while aging populations are adding pressure for earlier diagnosis and better disease management.

Why it matters: - Clinical biomarkers are becoming a core tool for personalized medicine, earlier diagnosis and treatment selection. - Faster market growth signals more demand for diagnostic testing, biomarker-guided drug development and translational research across healthcare systems. - An aging global population is increasing the need for markers that can help detect and manage age-related disease sooner.

What happened: - The Business Research Company released its Clinical Biomarkers Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report estimates the clinical biomarkers market at $37.6 billion in 2026, up from $33.75 billion in 2025. - The report forecasts the market will reach $59.44 billion by 2030. - North America held the largest share of the market in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

The details: - The report puts historic growth at a 11.4% compound annual growth rate from 2025 to 2026. - It projects a 12.1% CAGR through 2030. - Historic growth is tied to more biomedical research, higher clinical trial volumes, broader diagnostic testing, greater adoption of molecular diagnostics and advances in analytical technologies. - Future growth is expected to come from demand for personalized therapies, biomarker-guided drug development, translational research programs, real-world clinical data and sequencing technologies. - The report flags precision medicine biomarkers, multi-omics biomarker platforms, AI-powered biomarker analytics, companion diagnostics and early disease detection as major trends. - Clinical biomarkers are measurable biological indicators of normal or abnormal bodily functions, including specific chemicals and physiological metrics. - The report says these biomarkers help clinicians understand health status, disease progression and potential therapeutic targets. - The World Health Organization reported in February 2025 that the global population aged 60 and above is expected to rise from 1.1 billion in 2023 to 1.4 billion by 2030. - The company offers a free sample of the report here. - The full report is available here.

Between the lines: - The forecast suggests biomarker tools are moving from niche research inputs toward broader clinical and commercial use. - The combination of aging demographics, sequencing adoption and AI analytics points to a market that is expanding on both demand and capability. - North America's lead suggests the region remains the center of spending and infrastructure, even as other regions are included in the growth outlook.

What's next: - The report expects wider adoption of precision medicine biomarkers and companion diagnostics to continue shaping market growth. - More investment in biomarker-guided drug development and translational research is likely to support the forecast through 2030. - The company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis.

The bottom line: - Clinical biomarkers are on a strong growth path, with the market forecast to nearly double from 2025 levels by 2030 as healthcare shifts toward more precise, data-driven care.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Healthy Living Europe

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Healthy Living Europe

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.